km-2210 and Thrombocytopenia

km-2210 has been researched along with Thrombocytopenia* in 1 studies

Other Studies

1 other study(ies) available for km-2210 and Thrombocytopenia

Article	Year
[Early phase II trial of bestrabucil in hematological malignancies]. Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:6 Thirty-three patients with various hematological malignancies were treated with Bestrabucil, the benzoate of an estradiol-chlorambucil conjugate, at doses of 50-300 mg daily p.o., consecutively. Nineteen patients had previously received chemotherapy. Of 29 evaluable patients, there were one CR and three PRs among 6 patients with chronic lymphocytic leukemia, two CRs and one PR among 4 patients with malignant lymphoma, two PRs among 3 patients with adult T-cell leukemia, one PR among 4 patients with macroglobulinemia, one PR for one patient with essential thrombocythemia, and one PR for a patient with chronic myelocytic leukemia. Main side effects included G1 symptoms (14%), estradiol-related symptoms (24%) and myelosuppression (32%). Topics: Adult; Aged; Chlorambucil; Drug Administration Schedule; Drug Evaluation; Estradiol; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukopenia; Lymphoma; Male; Middle Aged; Thrombocytopenia	1986

Article

Year

[Early phase II trial of bestrabucil in hematological malignancies].

Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:6

Thirty-three patients with various hematological malignancies were treated with Bestrabucil, the benzoate of an estradiol-chlorambucil conjugate, at doses of 50-300 mg daily p.o., consecutively. Nineteen patients had previously received chemotherapy. Of 29 evaluable patients, there were one CR and three PRs among 6 patients with chronic lymphocytic leukemia, two CRs and one PR among 4 patients with malignant lymphoma, two PRs among 3 patients with adult T-cell leukemia, one PR among 4 patients with macroglobulinemia, one PR for one patient with essential thrombocythemia, and one PR for a patient with chronic myelocytic leukemia. Main side effects included G1 symptoms (14%), estradiol-related symptoms (24%) and myelosuppression (32%).

Topics: Adult; Aged; Chlorambucil; Drug Administration Schedule; Drug Evaluation; Estradiol; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukopenia; Lymphoma; Male; Middle Aged; Thrombocytopenia

1986